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Background: Numerous studies have reported a relationship between oral contraceptives use 
and cardiovascular disease, altered levels of coagulation factors and thrombosis. The goal of 
this study was to examine the effect of Combined oral contraceptive (COC, Duofem) on some 
physiological parameters and elucidate possible mechanism of action in female wistar rats.  
Methods: Forty (40) female wistar rats aged 10-12 weeks weighing 180-250 g were used for 
the study. They were divided into four groups (A-D) of 10 rats each comprising 5 treated and 5 
control rats.   The treated rats received (by intragastric administration), 0.6mg/kg body weight 
of COC for 36, 48, 60 and 72 days in five-day cycles (four-days treatment with one-day 
break). The COC was given in 5-day cycles (4-day treatment with 1-day break). An 
autoanalyzer was used to perform a complete blood count (CBC or FBC). Enzyme-linked 
immunosorbent assay (ELISA) was used for the quantitative determination of Protein C and S 
Antigen in citrated rat plasma. Antithrombin (AT) was determined by Chromogenic Assays. 
Prothrombin time (PT), Activated partial thromboplastin time (APTT) were performed using 
Sysmex CA-6000 Coagulation Analyzer.  Serum electrolytes were determined using Audicom 
AC99000 and liver function tests by ELISA method. Erythropoietin was determined using rat 
EPO ELISA kit. Fibrinogen was estimated by Clauss Assay. Results: There were significant 
decreases in haemoglobin (Hb), packed cell volume (PCV), Red blood cell (RBC) count, white 
blood cell (WBC) counts, lymphocytes (L), prothrombin time (PT) concentration, fibrinogen 
(Fib) concentration, antithrombin (AT) concentration , protein C (PC), protein S (PS), 
interleukin-6 (IL-6) and interleukin-11 (IL-11) in all treated groups compared to controls (P< 
0.05, respectively); in contrast, activities of alkaline phosphate (ALP), aspartate 
aminotransferase (AST), and alanine aminotransferase (ALT) as well as sodium and potassium 
were increased. There were no significant changes in APTT, mean platelet volume (MPV), 
EPO concentration, MCH, MCV, MCHC, Neutrophil, Eosinophil, Basophil, Bicarbonate and 
Chloride in all treated groups compared to controls. Most of the changes in the Physiological 
parameters were observed in long term exposure group C and group D. Conclusion: Long 
term used of combined oral contraceptives may lead to more complications than short time 
use. COC users should be monitored for some physiological parameters. 
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Introduction   
Contraception is the intentional prevention of 
fertilization from taking place through the use of 
various devices, sexual practices, barrier methods and 
hormonal contraception. Contraception is as old as 
human existence. For centuries, humans have relied on 
their imagination to avoid pregnancy. 
Oral contraceptives are a simple form of contraception 
used by women worldwide. The oral contraceptive is 
one of the greatest and most influential developments 
of the twentieth century. It is regarded as the most 
reliable method of contraception, and one of the easiest. 
They are widely available in most pharmacies and 
chemist shops. Oral contraceptives are highly reliable, 
non-permanent means of contraception after the rhythm 
method when correctly applied. Proper medication can 
achieve a successful rate of contraception as high as 
98% or above (Beral, 1977). Oral contraceptives 
prevent pregnancy primarily by inhibiting ovulation 
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through the combined actions of progestin and 
estrogen. Progestin inhibits ovulation by suppressing 
the cyclical release of luteinizing hormone (LH) from 
the anterior pituitary gland. Progestin also creates thick 
cervical mucus that slows sperm transport and inhibits 
capacitation (the activation enzymes that permit the 
sperm to penetrate the ovum). Estrogen in 
contraceptives contributes to ovulation inhibition by 
suppressing the release of follicle-stimulating hormone 
(FSH) and LH (Campton, 2001). 
Global family planning programmes have been in 
existence in the developed world for several decades 
and are primarily designed to supply couples with the 
methods of family planning that best suit their needs. 
Birth control is a major factor in public health and 
welfare, preserving the general and reproductive health 
of women and allowing them to choose the movement 
of a planned pregnancy (WHO, 2009). The World 
Health organization (WHO) and other global 
organizations are seeking ways to increase the amount 
of information and access people have to contraception 






Contraception is an important aspect of reproductive 
health and plays a major role in the prevention of 
unwanted pregnancy arising from rape for example. It 
is therefore a significant factor in reduction of induced 
abortion rate and improvement in maternal health care 
(Echendu, et al., 2011).  
 
 
Oral contraceptives had been reported to have 
beneficial effects in reducing the incidence of pelvic 
inflammatory disease, decrease risk of ectopic 
pregnancy, benign breast lesions, ovarian and 
endometrial cancers, protection against osteoporosis 
and rheumatoid arthritis among the users (Vessey, 
1995). Oral contraceptives are sometimes used to treat 
heavy or irregular menstruation and endometriosis. 
Oral contraceptive agents can also be used in hormonal 
replacement therapy, and in the emergency post-coital 
contraception. Oral contraceptive decreases the risk of 
ectopic pregnancy, benign breast lesions, ovarian and 
endometrial cancers, and offer protection against 
osteoporosis and rheumatoid arthritis (Rosing, 1999). 
Despite the general acceptability and the obvious 
advantages that have been attributed to oral 
contraceptive use, some serious side effects have been 
reported in women taking them. Studies have indicated 
a relationship of oral contraceptives use and 
cardiovascular disease, altered levels of coagulation 
factors, thrombosis, platelet changes, atherosclerosis 
and multiple sclerosis. Estrogen has been known to 
have prothrombin effects and elevates cardiovascular 
and venous thromboembolism risk (Margolis et al, 
2007).  
There is little or no data on the effects of Combined 
Oral Contraceptives on haematological parameters, 
especially the growth factors such as the cytokines or 
interlukin-11 and 6, and erythropoietin. Also, little or 
no data have been established in Liver Function Test, 
Serum Electrolytes, Fibrinogen, Antithrombin, Protein 
C and Protein S, using animal model. It is hoped that 
the study might throw some light on the need of 
monitoring the risks of taking COC (Duofem). 
 The world population is now seven billion. Nigeria’s 
population is estimated to be 176 million and will reach 
400 million by the year 2050 (Carl, 2011). Rapid 
population growths would have a detrimental effect on 
socioeconomic development of Nigeria. There is a 
concern over population explosion in Nigeria and the 
drive to control it is leading to indiscriminate used of 
oral contraceptives. Oral contraceptives are used for 
preventing abortion, unplanned pregnancies resulting 
from rape and teenage pregnancies. The effective 
control of reproduction can be essential for child 
spacing and to allow the woman to achieve her 
individual goals and to contribute to her sense of 
wellbeing. Unintended pregnancy leads to induced 
abortion which is not legalized in Nigeria, except to 
save the woman`s life. The primary focus of this study 
is to investigate the possible effects of oral 
contraceptives, their possible mechanism of actions and 
any associated side effects. The knowledge obtained 
might provide useful intervention towards solving the 
problem(s). Thus, safety in the use of contraceptives 
and improvement in the health of the user are assured. 
 
 Materials and Methods 
Drugs 
The combined oral contraceptive used is DUOFEM®. 
They were obtained from family clinic, Ahmadu Bello 
University Teaching Hospital, Shika-Zaria, and from 
the Society for Family Health (SFH) Abuja, Nigeria. 
COCs DUOFEM® tablets which combined ethinyl 
estradiol and Norgestrel were manufactured by Wyeth 
Ayerst (USA) and packed and marketed by the Society 
for Family Health, Lagos, Nigeria. DUOFEM® is a 
child spacing pill containing ferrous fumarate tablets. 
Each DUOFEM cycle contains 28 pills; each white 
tablet contains 0.3mg Norgestrel and 0.03mg 
Ethinglestradiol and each brown tablet contains 75mg 
ferrous fumarate. DUOFEM® has a molecular weight 
of 312.4458g/mol (Chitturi et al, 2003). 
Forty (40) female wistar rats aged 10-12 weeks 
weighing 180-250 g were used for the study. They were 
divided into four groups of 10 rats each comprising 5 
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treated and 5 control rats. The treated rats received 
0.6mg/kg body weight of COC intragastically using 
oral gavage syringe for 36, 48, 60 and 72 days in five-
day cycles (four-days treatment with one-day break). 
The COC was given intragastically in 5-day cycles (4-
day treatment with 1-day break). All controls were 
given fresh water ad libitum daily for the period of the 
experiment. Experimental animals in the study were 
treated in accordance with the National Protection 
Laws of Animal Welfare (Akinsanya et al, 2010). 
Ethical clearance was obtained from the Ahmadu Bello 
University Animal Ethical Committee. 
Other reagents and chemicals used were of analytical 
grade and of the purest quality available commercially. 
Animals were sacrificed after anaesthesia with 
chloroform and 5ml of blood was obtained via cardiac 
puncture and placed in plain and EDTA bottles. A 
haematology analyzer was used to perform a complete 
blood count (CBC or FBC). An enzyme-linked 
immunosorbent assay (ELISA) was used for the 
quantitative determination of Protein C and S Antigen 
in citrated rat plasma. Antithrombin (AT) was 
determined by Chromogenic Assays.  Prothrombin time 
(PT), Activated partial thromboplastin time (APTT) 
were performed using Sysmex CA-6000 Coagulation 
Analyzer. Serum electrolytes determined using 
Audicom AC99000. Interleukin 11 and 6 (IL-11, IL-6), 
erythropoietin (EPO) and liver function tests were 
determined by ELISA method. Fibrinogen was 
estimated by Clauss Assay (Clauss, 1957).  
 
Statistical Analysis 
The result obtained from this study was analyzed using 
SPSS version 20 for windows. Analysis of Variance 
(ANOVA) was used to compare means, and values 
were compared at P < 0.05. Post Hoc multiple 
comparisons for significant differences between groups 
were established by Turkey’s HSD. All the data are 
expressed as Mean ± Standard Error of Mean (SEM). 
 
RESULTS 
The effects of COC (DUOFEM) on Haematological 
and Biochemical parameters in female wistar rats were 
obtained in this study. There were significant decrease 
in haemoglobin (Hb) packed cell volume (PCV), red 
blood cell (RBC), white blood cell (WBC) counts, 
lymphocytes (L), prothrombin time (PT), fibrinogen 
(Fib), antithrombin (AT), protein C (PC), protein S 
(PS), interleukin-6 (IL-6) and interleukin-11 (IL-11) in 
all treated groups compared to controls (P< 0.05). 
There was significant increase in alkaline phosphate 
(ALP), aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), sodium and potassium in all  
 
Table 1: Effects of Combined Oral Contraceptives on 
Some Haematological Parameters in Female Rats 
 
*- significant (P<0.05). 
 
Table 2: The Effects of Combined Oral Contraceptives on Some haematological  
    Parameters in Female Wistar Rats 
 
*- significant (P<0.05). Neutrophils and monocytes were lowest for treated group C (60 Days), while Lymphocytes, 
Eosinophil, MPV, MCH and MCHC were lowest in treated group D (72 Days).
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Table 3: The Effects of Combined Oral Contraceptives on some Haemostatic Parameters   and Cytokines 
in Female Wistar Rats 
 
 
*-significant (P<0.05). The lowest values of PT, IL-6 and Fibrinogen were observed in the treated group 
D (72 Days). 
 
treated groups compared to controls (P< 0.05). There 
were however no significant changes in activated 
partial thromboplastin time (APTT), mean platelet 
volume (MPV), erythropoietin (EPO), MCH, MCV, 
MCHC, Neutrophil, Eosinophil, Basophil, Bicarbonate 
and Chloride in all treated groups compared to controls. 
 
Table 4: The Effects of Combined Oral Contraceptives on 
Some Anticoagulants in Female Wistar Rats 
 
*-significant (P<0.05). The lowest values of AT, PC and PS 
were observed in treated group D (72 Days).  
Most of the changes were observed in long term 
exposure to COC. The histology of the kidney shows 
no morphological changes in both treated groups and 
controls. Changes were however observed in the 
morphology of hepatocytes in the liver which was 
infiltrated with fats in groups C and D. 
 
Table 5: The Effects of Combined Oral Contraceptives on 
Some Liver Enzymes in Female Wistar Rats 
 
*- Significant (P<0.05). The highest values of ALP, ALT and 
AST were observed in treated group D (72 Days) 
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In this study the effect of COC on some Physiological 
parameters in female wistar rats was investigated. The 
result shows a reduction in haemoglobin(Hb), Packed 
cell volume(PCV), Red blood cell (RBC), White blood 
cell (WBC) counts and lymphocytes in all the groups 
that were given COC, compared to the controls (P<0-
05 respectively).  
 
Table 6: The Effects of Combined Oral Contraceptives on 




The finding of lower Hb, PCV, RBC, WBC and 
Lymphocytes agrees with the finding of Sajida et al. 
(2006). The finding is however contrary to that of other 
investigators like Bulur et al. (2006), Babatunde et al. 
(2003) and Abdalla (2008), who reported no changes in 
full blood count in women on COC. The least values of 
Hb, PCV and RBC were found in group D. It could be 
that the use of COC for a longer period may lead to 
anaemia. The finding of lower Hb, PCV and RBC 
counts in COC treated groups compared to controls 
may be as a result of the haemodilautoary effect of 
estrogen and the effect of estrogen on the cytokines like 
interleukin-11 and interleukin -6. The findings of lower 
values of WBC counts in COC treated groups suggest 
that prolonged use of COC may make the user 
susceptible to nonspecific infection and thus altered 
immune response. 
The findings of lower WBC count in COC treated 
groups was in agreement with that of Sajida et al. 
(2006), and contrary to the findings of Surasak et al. 
(2007) who observed no changes in WBC count and 
that of Araz et al. (2009) who observed increase in 
WBC count in COC treated female wistar rats. The 
difference may be as a result of the use of different 
COC with different concentration of estrogen and 
progesterone and the  duration of  use. There  were   no  
 
Plate 1: Photomicrographs of experimental groups  - Liver 
sections; Shows Transverse Sections of Liver. Group A and 
B Showed Normal Liver Architecture with the Central Vein 
(CV), Sinusoids (S) and Hepatocytes (H) Appearing Normal. 
Mononuclear Cells (MNC) were Noted in Group C and D 
Respectively and Dilated Central Vein (DCV) was Observed 
in Group D (×250) H & E 
 
 
Plate 2: Photomicrographs of experimental groups  - Kidney 
sections. Shows Normal Architectures of Longitudinal 
Sections of kidney. The Bowman’s Capsules (BC), 
Glomerulus (G), and the Kidney Tubules (KT ) of the 
Kidney Sections in Group A, B, C and D all Appeared 
Normal (×250) H&E 
 
 
significant changes observed in COC treated groups in 
platelet counts and mean platelet volume (MPV) 
compared to the controls. This finding agrees with that 
of Surasak et al. (2007), Peter (2013), Bulur et al. 
(2006) and Babatunde et al. (2003). The observation 
was however contrary to that of Sajida et al. (2006) 
who reported significant increase on MPV in subjects 
on COC.  There were no significant changes in MCV, 
MCH, Neutrophil, Eosinophil and Basophil counts in 
COC treated groups compared to the controls. This 
finding is in agreement with that of Peter (2013), Bulur 
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et al. (2006) and Babatunde et al. (2013), and contrary 
to the findings of Sajida et al. (2006). In general, the 
use of COC in female wistar rats suppressed 
haemopoiesis in this study resulting in lowering of Hb, 
PCV, RBC and WBC counts. 
There was no significant change in serum 
erythropoietin level in all compared with the controls. 
This finding is contrary to that of Prechile et al. (1972) 
who found that estradiol benzoate inhibited the 
production of erythropoietin (EPO). Erythropoietin 
promotes the survival, proliferation and differentiation 
of erythrocytic progenitors. EPO deficiency is the 
primary cause of the anaemia in chronic kidney disease. 
It appears COC has little or no effect in EPO 
production. Decreased RBC count in this study may not 
be as a result of COC effect on EPO. There was 
decrease fibrinogen levels in all the COC treated 
groups compared to the control. This finding differs 
from that of Eliana et al. (2014) and Peter et al. (2013) 
who reported increase in fibrinogen level in women 
taking COC. The finding is also contrary to that of 
Akhigbe et al. (2008) who found no significant change 
in fibrinogen level in female wistar rats treated with 
COC. The depletion of fibrinogen observed in the 
present study might result in coagulopathy. 
The association between increase in plasma fibrinogen 
and thrombosis and the risk of myocardial infarction 
are well established. Higher level of fibrinogen raises 
the risk of stroke. Damage to the liver may be the cause 
of deficiency in fibrinogen level by a third generation 
COC (DUOFEM).This may reduce risk of thrombosis 
in users. Fibrinogen functions as a messenger molecule 
that coordinates and regulates the body response to 
inflammation. Low fibrinogen levels are associated 
with low risk of cardiovascular diseases. Prothrombin 
Time (PT) significantly reduce in all the COC treated 
groups compare to the controls (P<0.001). There was 
no significant reduction in Activated Prothrombin Time 
(APTT). This finding agrees with that of Abdalla et al. 
(2008) in Sudan found significant reduction in PT and 
APTT in women taking COC. Babatunde et al. (2008) 
found that there was no significant change in the level 
of APTT in Nigerian women taking COC for three 
months. This is in agreement with the finding of this 
study. 
Also, Eliana et al. (2014) found reduced PT and APTT 
in Albanian women taking COC. Reduction in 
prothrombin time may be as a result of reduced serum 
level of fibrinogen. Estrogen is also said to increase 
coagulation factors leading to decreased prothrombin 
time. The finding of this study is also in agreement with 
that of Ahmed et al. (2008) and Nasir et al. (2008) who 
reported a significant reduction in APTT and PT in 
women taking COC. The COC (DUOFEM) used in this 
study is likely to cause prothrombotic effect. This may 
lead to hypercoagulability and thrombosis. 
There was a significant decrease in serum level of 
interleukin-6 (IL-6) and a slight decrease in serum 
interleukin-11 (IL-11). Estrogen is able to decrease IL-
6 expression by blocking the estroblast’s synthesis of 
IL-6 receptors (Jean et al., 1992). IL-11 and IL-6 are 
haemopoiesis-promoting factors capable of enhancing 
the growth of myloid, erythroid and megakaryiocytic 
progenitor cells. They are capable of mediating a 
complex array of pro- and anti-inflammatory effects. 
Reduction in IL-11 and IL-6 may be responsible for 
decreased RBC, PCV, WBC and platelet counts in this 
study. IL-6 produces C-Reactive Protein (CRP) which 
leads to cardiovascular risk. Experimental studies have 
shown strong correlations between the risk of 
cardiovascular diseases and inflammatory markers such 
as CRP and tissue neurosis factor-α (TNF α) 
(Subhadeep et al., 2008). IL-6 is a pleotropic cytokine 
which stimulates B-lymphocyte and T-lymphocyte 
differentiation and activates macrophages and NK cells. 
The finding of reduced serum IL-6 is in agreement with 
the finding of Straub et al. (2000) who reported 
decrease serum level of IL-6 in menopausal women 
taking hormonal replacement therapy. Interleukin 6 
(IL-6), promptly and transiently produced in response 
to infections and tissue injuries, contributes to host 
defence through the stimulation of acute phase 
responses, hematopoiesis, and immune reactions. IL-6 
has been demonstrated to have a pivotal role in the 
pathogenesis of rheumatoid arthritis, Castleman’s 
disease and Crohn’s disease exemplified by the use of 
an anti-IL-6 biological therapy. However, IL-6 is also 
associated with the autoimmune disease systemic 
sclerosis and has been shown to be directly fibrotic 
(Rachon et al.2002). 
There was a significant decrease in serum level of 
antithrombin (AT), protein C (PC) and protein S (PS) 
in COC treated groups compared to the controls. 
Proteins C and S and antithrombin are components of 
the anticoagulant system. In haemostasis, the 
procoagulant system is in balance with the 
anticoagulant and fibrinolytic system (Karl et al., 
2008). A decrease in AT, PC and PS may cause 
thrombosis. This finding is in agreement with that of 
Soare (2010) and John et al. (2012) who observed 
lower values of PC in women using oral contraceptives. 
Decreased AT, PC and PS may be responsible for the 
changes observed in haemostasis. AT, PC and PS are 
vitamin K-dependent. Damage to the liver may be 
responsible for the reduction of serum level of AT, PC 
and PS in COC treated groups. 
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There were increased values of alkaline phosphatase 
(ALP), Aspartate aminotransferase (AST) and Alanine 
aminotransferase (ALT) in all COC treated groups 
compared to controls (P<0.001). The liver plays a 
central role in the metabolism of estrogens and 
progesterones. COC acts directly or indirectly on the 
liver to produce a variety of biological effects which 
have both physiological and pathological significance 
(Trussel, 2007). Higher levels of liver enzymes in the 
blood streams are prime indicators of liver damage. The 
use of COCs has been rarely associated with liver 
tumours, both benign (hepaticadeomas and nodular 
hyperplasia) and malignant (hepatocellular carcinoma). 
The finding of increased liver enzymes is in agreement 
with that of Dickerson et al. (1992) and contrary to that 
of Surasak et al. (2007) who found no changes in liver 
enzymes in women on COC. 
Raised serum level of ALP, AST and ALT in treated 
groups may be due to functional alterations involving 
the hepatic excretory mechanism.  There was a 
significant increase in serum sodium level in group D ( 
P<0.044) compared to the control. There was no 
significant increase in serum sodium level in treated 
groups A (36 days), B and C compared to the controls. 
Potassium was significantly increased in groups C (60 
days) and D Sodium retention has been reported in 
women taking COC (Akhigbe et al., 2008). The result 
in this study is contrary to that of Taneepanichskul et 
al. (2007) who reported no significant changes in 
electrolytes in women taking COC. 
Hypertension occasionally occurs in women receiving 
estrogen-progesterone combination for contraception. 
Estrogen raises the plasma level of renin and increases 
the production rate of aldosterone which leads to water 
and sodium retention (Nicholas et al., 1974; Kang et 
al., 2011), reported reduced potassium level and 
increased sodium level in female rats. There was no 
significant change in bicarbonate and chloride in 
treated groups compared to the controls. Body 
electrolyte balances are critical for normal cellular 
function and maintaining adequate blood and plasma 
volume and osmolality. 
 
CONCLUSION 
COCs have evolved from one generation to 
another. The COC (DUOFEM) used in this study 
is a third generation COC. DUOFEM causes 
changes in Haematological and Biochemical 
parameters by decreasing the level of Hb, PCV, 
WBC, IL6 &11, Fibrinogen, Antithrombin, Protein 
C & S, and increasing the level of liver enzymes 
and serum electrolytes. The histology of the 
kidney shows no morphological changes in both 
treated groups and controls. Changes were 
however observed in the morphology of 
hepatocytes in the liver which was infiltrated with 
fats in groups C and D.  
We recommend further study at the gene level 
devoted to COC (DUOFEM) effect on coagulation 
to clarify the mechanism by which the hormones 
influence the expression of circulating proteins in 
haemostasis. There is need for an effective, risk- 
free combined oral contraceptive. COC users should 
be monitored for some physiological parameters. 
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